Paper36650239
Tumor-specific intracellular delivery: peptide-guided transport of a catalytic toxin.
Allred CA and 5 others. Commun Biol, 2023. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Tumor-specific intracellular delivery: peptide-guided transport of a catalytic toxin. Papers, record 36650239. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36650239
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Lung Neoplasms | Major topic |
| Antineoplastic Agents | Major topic |
| Animals | |
| Humans | |
| Peptides | |
| Peptide Library |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 1R01CA164447-01 | U.S. Department of Health & Human Services | National Institutes of Health (NIH) | R01CA164447 | PubMed |
Source NIH RePORTER
References58
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 7542357 | Treatment of B-cell lymphomas with combination of bispecific antibodies and saporin. | Lancet | 1995 | https://conductscience.org/library/papers/7542357 | PubMed |
| 2 | 25758331 | Light-controlled endosomal escape of the novel CD133-targeting immunotoxin AC133-saporin by photochemical internalization - A minimally invasive cancer stem cell-targeting strategy. | J Control Release | 2015 | https://conductscience.org/library/papers/25758331 | PubMed |
| 3 | 17714513 | Lipopolyamine treatment increases the efficacy of intoxication with saporin and an anticancer saporin conjugate. | FEBS J | 2007 | https://conductscience.org/library/papers/17714513 | PubMed |
| 4 | 18935973 | Saporin induces multiple death pathways in lymphoma cells with different intensity and timing as compared to ricin. | Int J Biochem Cell Biol | 2009 | https://conductscience.org/library/papers/18935973 | PubMed |
| 5 | 24299061 | Combinatorial peptide libraries: mining for cell-binding peptides. | Chem Rev | 2014 | https://conductscience.org/library/papers/24299061 | PubMed |
| 6 | 27338475 | High in Vitro Anti-Tumor Efficacy of Dimeric Rituximab/Saporin-S6 Immunotoxin. | Toxins (Basel) | 2016 | https://conductscience.org/library/papers/27338475 | PubMed |
| 7 | 24670678 | Identification and characterization of a suite of tumor targeting peptides for non-small cell lung cancer. | Sci Rep | 2014 | https://conductscience.org/library/papers/24670678 | PubMed |
| 8 | 24195949 | Intrathecal substance P-saporin in the dog: efficacy in bone cancer pain. | Anesthesiology | 2013 | https://conductscience.org/library/papers/24195949 | PubMed |
| 9 | 19789305 | A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma. | Clin Cancer Res | 2009 | https://conductscience.org/library/papers/19789305 | PubMed |
| 10 | 28218037 | Immunotoxin: A new tool for cancer therapy. | Tumour Biol | 2017 | https://conductscience.org/library/papers/28218037 | PubMed |
| 11 | 19764990 | ATG-saporin-S6 immunotoxin: a new potent and selective drug to eliminate activated lymphocytes and lymphoma cells. | Br J Haematol | 2009 | https://conductscience.org/library/papers/19764990 | PubMed |
| 12 | 22475101 | Endocytosis and intracellular localisation of type 1 ribosome-inactivating protein saporin-s6. | J Biol Regul Homeost Agents | 2012 | https://conductscience.org/library/papers/22475101 | PubMed |
| 13 | 23643966 | Photochemical internalization of CD133-targeting immunotoxins efficiently depletes sarcoma cells with stem-like properties and reduces tumorigenicity. | Biochim Biophys Acta | 2013 | https://conductscience.org/library/papers/23643966 | PubMed |
| 14 | 32575752 | Development of Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer: An Update. | Biomolecules | 2020 | https://conductscience.org/library/papers/32575752 | PubMed |
| 15 | 31969331 | ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. | Clin Cancer Res | 2020 | https://conductscience.org/library/papers/31969331 | PubMed |
| 16 | 22069735 | Immunotoxins and other conjugates containing saporin-s6 for cancer therapy. | Toxins (Basel) | 2011 | https://conductscience.org/library/papers/22069735 | PubMed |
| 17 | 33536635 | Trends in peptide drug discovery. | Nat Rev Drug Discov | 2021 | https://conductscience.org/library/papers/33536635 | PubMed |
| 18 | 26912181 | Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design. | AAPS J | 2016 | https://conductscience.org/library/papers/26912181 | PubMed |
| 19 | 29870741 | Strategies to Reduce the Immunogenicity of Recombinant Immunotoxins. | Am J Pathol | 2018 | https://conductscience.org/library/papers/29870741 | PubMed |
| 20 | 28941284 | Targeted therapy of human glioblastoma via delivery of a toxin through a peptide directed to cell surface nucleolin. | J Cell Physiol | 2018 | https://conductscience.org/library/papers/28941284 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40817125 | HACD3 promotes malignant progression of NSCLC by suppressing the MKK7/MAPK10 signaling axis. | BMC Cancer | 2025 | https://conductscience.org/library/papers/40817125 | PubMed |
| 40672665 | Advancing Cancer-Targeted Nanotherapies with Tumor Homing Peptides. | ACS Pharmacol Transl Sci | 2025 | https://conductscience.org/library/papers/40672665 | PubMed |
| 39064917 | Cell-Penetrating Peptide-Mediated Biomolecule Transportation in Artificial Lipid Vesicles and Living Cells. | Molecules | 2024 | https://conductscience.org/library/papers/39064917 | PubMed |
| 38584554 | Neuropilin-1 Binding Peptide as Fusion to Diphtheria Toxin Induces Apoptosis in Non-small Cell Lung Cancer Cell Line. | Curr Pharm Des | 2024 | https://conductscience.org/library/papers/38584554 | PubMed |
Genes13
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36650239
GET https://conductscience.org/api/papers/v1/36650239/references?page=2